A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Public ClinicalTrials.gov record NCT05859074. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A First-In-Human Phase I, Open Label, Safety and Tolerability Study of Escalating Multiple Doses of Intratumoral MQ710, a Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, Alone and in Combination With the Systemic Checkpoint Inhibitor Pembrolizumab in Solid Tumors
Study identification
- NCT ID
- NCT05859074
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Enrollment
- 56 participants
Conditions and interventions
Conditions
- Adnexal Carcinoma
- Advanced Cancer
- Angiosarcoma
- BCC
- BCC - Basal Cell Carcinoma
- Basal Cell Carcinoma
- Cutaneous Neoplasm
- Cutaneous Squamous Cell Carcinoma
- Extramammary Paget Disease
- HNSCC
- Head and Neck Squamous Cell Carcinoma
- Kaposi Sarcoma
- Melanoma
- Merkel Cell Carcinoma
- Metastatic Cancer
- Refractory Cancer
- SCC - Squamous Cell Carcinoma
- Sebaceous Carcinoma
- Solid Tumor
Interventions
- MQ719 Biological
- Pembrolizumab Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 3, 2023
- Primary completion
- May 3, 2028
- Completion
- May 3, 2028
- Last update posted
- Dec 2, 2025
2023 – 2028
United States locations
- U.S. sites
- 7
- U.S. states
- 2
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge | New Jersey | 07920 | Recruiting |
| Memorial Sloan Kettering Monmouth (Limited protocol activities) | Middletown | New Jersey | 07748 | Recruiting |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale | New Jersey | 07645 | Recruiting |
| Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) | Commack | New York | 11725 | Active, not recruiting |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison | New York | 10604 | Active, not recruiting |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York | New York | 10065 | Recruiting |
| Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale | New York | 11553 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05859074, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 2, 2025 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05859074 live on ClinicalTrials.gov.